Skip to content

Net Income at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$1.66B+9.6%
Danaher logo
DanaherDHR
$1.03B+7.9%
Bruker logo
BrukerBRKR
$15.7M-6.5%
Revvity logo
RevvityRVTY
$40.72M-3.6%
Agilent Technologies logo
Agilent TechnologiesA
$339M+57.7%
Charles River Laboratories logo
Charles River LaboratoriesCRL
-$14.8M-157%

Other financials

Income statement

See full
Revenue$311.4M-1.5%
Gross profit$208.3M-2.9%
Operating income$75.5M+95.0%
Net income$51.0M+126%
EPS (diluted)$0.32+129%

Balance sheet

See full
Cash & equivalents$209.8M+49.2%
Total debt$290.3M-31.4%
Total equity$2.1B+3.3%
Total assets$2.6B-3.5%

Cash flow

See full
Operating cash flow$86.7M+111%
CapEx$9.1M-10.2%
Free cash flow$77.6M+150%

Valuation

See full
Market cap$9.07B-11.8%
Enterprise value$9.15B-13.6%
P/E60.6×+13.6×
P/S7.5×-1.0×

Profitability

See full
Gross margin65%-0.8pp
Operating margin14.2%-7.9pp
Net margin10.9%-6.7pp
FCF margin22.3%+4.0pp

Returns & leverage

See full
Return on equity6.5%-3.9pp
Debt / equity0.1×-0.1×
Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Bio-Techne’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Techne's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Techne's net income?
Bio-Techne (TECH) reported net income of $51.05M in Q1 2026.
How has Bio-Techne's net income changed year-over-year?
Bio-Techne's net income increased by 126.0% year-over-year, from $22.59M to $51.05M.
What is the long-term trend for Bio-Techne's net income?
Over 3 years (2021 to 2024), Bio-Techne's net income has grown at a 6.4% compound annual growth rate (CAGR), from $139.59M to $168.11M.
What does net income mean?
The total profit a company earns after all expenses are paid.
How do you interpret net income?
An increase indicates higher profitability and potential for reinvestment, while a decrease may signal operational challenges or rising costs.
How does net income compare across companies?
Standard across all public companies; peers in life sciences typically show consistent growth in this metric.